Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ACACB | O00763 | 13/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20239291 | 0.87 | ACACB (0.42) | DGAT2RAB9ANPC1ACACBTP53 | |
| SCHEMBL20239170 | 0.85 | DGAT2 (0.50) | SMN1; SMN2DGAT2RAB9ANPC1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL20239229 | 0.84 | DGAT2 (0.49) | SMN1; SMN2DGAT2RAB9ANPC1ALDH1A1 | |
| SCHEMBL28425724 | 0.84 | ACACB (0.38) | SMN1; SMN2DGAT2ACACBCA1CA2 | |
| SCHEMBL20239275 | 0.83 | CA1 (0.44) | SMN1; SMN2DGAT2RAB9ANPC1ALDH1A1 | |
| SCHEMBL20239319 | 0.74 | DGAT2 (0.60) | SMN1; SMN2DGAT2RAB9AALDH1A1CA1 | |
| SCHEMBL20239335 | 0.72 | SLC6A4 (0.43) | RAB9ANPC1ACACB | |
| SCHEMBL20239155 | 0.72 | ACACB (0.51) | ACACBALDH1A1 | |
| SCHEMBL20239261 | 0.72 | DGAT2 (0.51) | SMN1; SMN2DGAT2RAB9AALDH1A1 | |
| SCHEMBL20239218 | 0.72 | DGAT2 (0.47) | DGAT2RAB9ANPC1TP53ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | ELI LILY AND COMPANY (US) | 2018-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180162825-A1 | NOVEL DGAT2 INHIBITORS | DGAT2, DGAT1, LCAT | SMN1; SMN2 4828/4885DGAT2 1/4885RAB9A 1170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.